Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | RAPGEF4 | Q8WZA2 | 3/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7890511 | 0.79 | HRH3 (0.39) | CYP11B1CYP11B2HRH3RAPGEF4HTR1D | |
| SCHEMBL3807690 | 0.77 | HPGD (0.44) | CYP11B1CYP11B2HRH3RAPGEF4HTR1D | |
| SCHEMBL8997706 | 0.76 | HRH3 (0.34) | CYP11B1CYP11B2HRH3RAPGEF4HTR1D | |
| SCHEMBL6488234 | 0.75 | AGXT (0.44) | CYP11B1CYP11B2HRH3RAPGEF4HTR1D | |
| SCHEMBL8725962 | 0.75 | HRH3 (0.36) | CYP11B1CYP11B2HRH3RAPGEF4HTR1D | |
| SCHEMBL11783876 | 0.75 | ALDH1A1 (0.38) | CYP11B1CYP11B2HRH3RAPGEF4HTR1D | |
| SCHEMBL18461384 | 0.75 | HRH3 (0.36) | CYP11B1CYP11B2HRH3RAPGEF4HTR1D | |
| SCHEMBL18458915 | 0.75 | HRH3 (0.36) | CYP11B1CYP11B2HRH3RAPGEF4HTR1D | |
| SCHEMBL16241899 | 0.75 | SLC22A12 (0.38) | HTR1DALDH1A1LMNAKCNH2 | |
| SCHEMBL27983593 | 0.75 | HTR1D (0.37) | CYP11B1CYP11B2HRH3RAPGEF4HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933306-B2 | Hydroxamic and carboxylic acid derivatives | DARWIN DISCOVERY LTD. (GB) | 2005-08-23 | — | — | US | disclosed |
| EP-1030851-B1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LTD (GB) | 2005-01-12 | — | — | EP | disclosed |
| US-20040266764-A1 | Hydroxamic acid derivatives | HANNAH DUNCAN ROBERT | 2004-12-30 | — | — | US | disclosed |
| US-6809100-B2 | 2-(4-(4-FURAN-2-YLPHENYL)PIPERAZINE-1-SULFONYLMETHYL)-N-HYDROXY -3-METHYLBUTYRAMIDE, FOR EXAMPLE; TREATMENT OF CANCER, INFLAMMATION, OR AN AUTOIMMUNE, INFECTIOUS OR OCULAR DISEASE | DARWIN DISCOVERY LTD. (GB) | 2004-10-26 | — | — | US | disclosed |
| US-20040176362-A1 | Hydroxamic and carboxylic acid derivatives | BATTY DUNCAN (GB) | 2004-09-09 | — | — | US | disclosed |
| US-6787536-B2 | A HYDROXAMIC ACID COMPOUND CONTAINING HETEROAROMATIC RING ATTACHED TO SULFONYL GROUP THROUGH NITROGEN ATOM, INHIBITOR OF MATRIX METALLOPRETEINASE, USEFUL FOR TREATING DEGENERATIVE DISEASES AND CERTAIN CANCER | DARWIN DISCOVERY LIMITED (GB) | 2004-09-07 | — | — | US | disclosed |
| US-20040127717-A1 | Hydroxamic and carboxylic acid derivatives | MONTANA JOHN GARY (GB) | 2004-07-01 | — | — | US | disclosed |
| US-6734189-B2 | TETRAHYDRO-N-CARBOXYALKYLSULFONYLCARBOLINE DERIVATIVES, USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY INHIBITORS OF MATRIX METALLOPROTEINASE, ADAM, ADAM-TS ENZYMES, AND/OR TNF ALPHA -MEDIATED DISEASES | DARWIN DISCOVERY, LTD. (GB) | 2004-05-11 | — | — | US | disclosed |
| EP-0968182-B1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LTD (GB) | 2004-05-06 | — | — | EP | disclosed |
| US-6706719-B1 | COMPOUNDS WHICH HAVE THE PROPERTY OF INHIBITING THE ACTION OF METALLOPROTEINASES INVOLVED IN CONNECTIVE TISSUE BREAKDOWN | DARWIN DISCOVERY, LTD. (GB) | 2004-03-16 | — | — | US | disclosed |
| WO-1997012902-A1 | THIO-SUBSTITUTED PEPTIDES AS INHIBITORS FOR METALLOPROTEINASES AND TNF LIBERATION | DARWIN DISCOVERY LIMITED (GB) | 1997-04-10 | — | — | WO | disclosed |
| WO-1997012861-A1 | MERCAPTOAMIDE DERIVATIVES AND THEIR THERAPEUTIC USE | CHIROSCIENCE LIMITED (GB) | 1997-04-10 | — | — | WO | disclosed |
| WO-1997012887-A1 | PURINE AND GUANINE DERIVATIVES AS PNP INHIBITORS | CHIROSCIENCE LIMITED (GB) | 1997-04-10 | — | — | WO | disclosed |
| WO-1996035711-A1 | PEPTIDE COMPOUNDS WHICH INHIBIT METALLOPROTEINASE AND TNF LIBERATION, AND THEIR THERAPEUTIC USE | CHIROSCIENCE LIMITED (GB) | 1996-11-14 | — | — | WO | disclosed |
| WO-1996035712-A1 | PEPTIDYL COMPOUNDS WHICH INHIBIT METALLOPROTEINASE AND TNF LIBERATION AND THEIR THERAPEUTIC USE | CHIROSCIENCE LIMITED (GB) | 1996-11-14 | — | — | WO | disclosed |
| WO-1996035687-A1 | PEPTIDYL COMPOUNDS AND THEIR THERAPEUTIC USE | CHIROSCIENCE LIMITED (GB) | 1996-11-14 | — | — | WO | disclosed |
| WO-1996035714-A1 | PEPTIDE COMPOUNDS WHICH INHIBIT METALLOPROTEINASE AND TNF LIBERATION AND THEIR THERAPEUTIC USES | CHIROSCIENCE LIMITED (GB) | 1996-11-14 | — | — | WO | disclosed |
| WO-1996011209-A1 | PEPTIDYL COMPOUNDS AND THEIR THERAPEUTIC USE AS INHIBITORS OF METALLOPROTEASES | CHIROSCIENCE LIMITED (GB) | 1996-04-18 | — | — | WO | disclosed |
| WO-1996011200-A1 | PURINE AND GUANINE COMPOUNDS AS INHIBITORS OF PNP | CHIROSCIENCE LIMITED (GB) | 1996-04-18 | — | — | WO | disclosed |
| WO-1991007378-A1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE DIURETIC AGENTS | PFIZER LIMITED (GB) | 1991-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176362-A1 | Hydroxamic and carboxylic acid derivatives | ADAM17, ADAM10, ADAM9 | CYP11B1 1113/4885CYP11B2 1210/4885HRH3 936/4885 |
| US-20040127717-A1 | Hydroxamic and carboxylic acid derivatives | HCAR1, HCAR2, CBR1 | CYP11B1 886/4885CYP11B2 1141/4885HRH3 78/4885 |
| US-20040266764-A1 | Hydroxamic acid derivatives | ADAM17, ADAM10, ADAM33 | CYP11B1 2766/4885CYP11B2 2953/4885HRH3 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.